Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
CAR-T cell therapies may represent a viable treatment for relapsed or refractory disease, but further studies will be needed to refine patient selection.
People with HIV who delay initiation of anti-retroviral therapy have permanent loss of memory T cells in the skin, which may explain their increased risk of skin cancer.
